Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TYK2 inhibitor

- PMLiVE

Takeda pays $60m for vaccine company LigoCyte

Gains first-in-class norovirus candidate and new vaccine platform

- PMLiVE

Takeda completes new manufacturing facility in Russia

Expands Japanese firm’s presence in key emerging market

- PMLiVE

Takeda’s Revestive becomes first approved drug in Europe for short bowel syndrome

Can reduce dependency on intravenous feeding

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links